sever
mammalian
arenavirus
mammarenavirus
caus
hemorrhag
fever
human
pose
seriou
public
health
concern
endem
region
addit
mount
evid
indic
worldwidedistribut
prototyp
mammarenaviru
lymphocyt
choriomening
viru
lcmv
neglect
human
pathogen
clinic
signific
concern
humanpathogen
mammarenavirus
exacerb
lack
licens
vaccin
current
antimammarenaviru
therapi
limit
offlabel
use
ribavirin
partial
effect
detail
understand
virushostcel
interact
may
facilit
develop
novel
antimammarenaviru
strategi
target
compon
hostcel
machineri
requir
effici
viru
multipl
document
gener
recombin
lcmv
encod
nucleoprotein
np
contain
affin
tag
rlcmvstrepnp
use
captur
npinteractom
infect
cell
proteom
approach
combin
genet
pharmacolog
valid
assay
identifi
atpas
na
k
transport
subunit
alpha
prohibitin
phb
provir
factor
cellbas
assay
reveal
phb
involv
differ
step
viru
life
cycl
accordingli
observ
synergist
inhibitori
effect
lcmv
multipl
combin
phb
inhibitor
show
inhibitor
suppress
multipl
lassa
viru
candid
liveattenu
vaccin
strain
viru
suggest
requir
viru
multipl
conserv
among
genet
distantli
relat
mammarenavirus
find
suggest
clinic
approv
inhibitor
like
digoxin
could
repurpos
treat
infect
mammarenavirus
pathogen
human
introduct
mammarenavirus
arenavirida
mammarenaviru
caus
chronic
infect
rodent
worldwid
invas
human
dwell
infect
rodent
result
human
infect
mucos
exposur
aerosol
direct
contact
abrad
skin
infecti
materi
sever
mammarenavirus
caus
viral
hemorrhag
fever
vhf
human
pose
import
public
health
problem
endem
area
mammarenavirus
classifi
two
main
group
old
world
ow
new
world
nw
ow
lassa
viru
lasv
caus
agent
lassa
fever
lf
signific
ow
mammarenavir
pathogen
lasv
estim
infect
sever
hundr
thousand
individu
annual
western
africa
result
high
number
lf
case
associ
high
morbid
lethal
moreov
lasv
endem
region
expand
associ
recent
identifi
mammarenaviru
lujo
viru
vhf
outbreak
southern
africa
rais
concern
emerg
novel
vhfcaus
mammarenavirus
signific
nw
mammarenaviru
viru
junv
caus
argentinian
hemorrhag
fever
worldwidedistribut
ow
mammarenaviru
lymphocyt
choriomening
viru
lcmv
neglect
human
pathogen
clinic
signific
especi
congenit
infect
moreov
lcmv
pose
particular
threat
immunocompromis
individu
illustr
fatal
case
lcmv
infect
associ
organ
transplant
howev
lcmv
research
safe
perform
contain
rather
contain
necessari
live
lasv
junv
research
us
food
drug
administr
fda
licens
vaccin
avail
treatment
arenaviru
infect
although
live
attenu
vaccin
strain
junv
candid
licens
argentina
likewis
current
antimammarenaviru
therapi
limit
offlabel
use
nucleosid
analogu
ribavirin
partial
effect
caus
signific
side
effect
develop
effect
antimammarenaviru
drug
hamper
lack
detail
understand
virushostcel
interact
requir
mammarenaviru
multipl
could
repres
amen
target
antivir
therapi
potenti
problem
overexpress
singl
viral
gene
product
may
potenti
ppi
interact
relev
cours
natur
viru
infect
overcom
issu
design
recombin
lcmv
rlcmv
encod
tandem
wshpqfek
ggg
wshpqfek
streptag
fuse
aminoterminu
np
rlcmvstrepnp
fig
facilit
identif
specif
ppi
np
host
cell
protein
use
mammarenaviru
triseg
platform
design
express
cterminu
streptag
version
enhanc
green
fluoresc
protein
use
neg
control
fig
rescu
rlcmvstrepnp
confirm
express
streptag
np
egfp
rlcmv
strepnpand
cell
respect
fig
next
examin
growth
properti
rlcmvstrepnp
three
differ
cell
line
hamster
human
nonhuman
primat
vero
cell
respect
fig
fit
rlcmvstrepnp
modestli
decreas
compar
observ
wildtyp
wt
armstrong
rlcmv
arm
clone
rlcmv
strain
lcmv
howev
rlcmvstrepnp
wtlike
growth
kinet
reach
high
titer
wt
lcmv
infect
rlcmvstrepnp
prevent
product
bioactiv
ifni
cell
respons
sendai
viru
sev
infect
determin
use
ifn
bioassay
base
protect
cytopath
effect
cpe
induc
infect
vesicular
stomat
viru
vsv
fig
vero
cell
treat
h
tissu
cultur
supernat
tc
cell
infect
first
wt
lcmv
rlcmvstrep
follow
h
infect
sev
remain
fulli
suscept
vsvinduc
cpe
contrast
vero
cell
treat
tc
cell
infect
rlcmvnp
mutant
unabl
prevent
induct
ifni
subsequ
sev
protect
vsv
induc
cpe
select
human
cell
line
lung
epitheli
cell
one
initi
cell
target
human
follow
inhal
mammarenavirion
infect
cell
multipl
infect
moi
either
rlcmvstrepnp
fig
h
postinocul
pi
prepar
total
cell
lysat
pulldown
pd
assay
use
sepharos
resin
coat
streptactin
aliquot
protein
complex
present
pd
sampl
fraction
sodium
dodecyl
sulfatepolyacrylamid
gel
electrophoresi
sdspage
fig
follow
sypro
rubi
protein
gel
stain
compar
pattern
stain
protein
band
detect
rlcmvstrepnpand
sampl
confirm
presenc
strepnp
egfpstrep
pertin
sampl
fig
protein
complex
rest
eluat
pd
sampl
concentr
trichloroacet
acid
tca
precipit
subject
trypsin
digest
fig
digest
peptid
subject
liquid
chromatographytandem
mass
spectrometri
lcmsm
analysi
use
hybrid
mass
spectromet
consist
linear
quadrupol
ion
dual
cell
trap
ltq
velo
orbitrap
analys
classifi
hostcel
protein
identifi
lcmsm
analysi
two
independ
biolog
replic
two
group
protein
found
strepnp
pd
sampl
least
five
spectral
count
tabl
protein
found
strepnp
egfpstrep
pd
sampl
five
higher
spectral
count
strepnp
sampl
least
higher
spectral
count
strepnp
pd
compar
egfp
pd
sampl
tabl
filter
data
use
criteria
result
identif
candid
hostcel
protein
npinteract
partner
among
protein
found
present
npand
egfppd
sampl
spectral
count
nppd
sampl
less
twofold
higher
correspond
spectral
count
egfppd
sampl
fig
tabl
base
criteria
describ
consid
protein
highli
unlik
specif
npinteractor
involv
lcmv
life
cycl
therefor
consid
hit
analysi
howev
acknowledg
formal
rule
hit
could
still
play
role
life
cycl
lcmv
protein
annot
evolutionari
relationship
panther
protein
famili
classif
biolog
process
npinteract
protein
candid
reveal
larg
number
protein
involv
metabol
cellular
process
fig
also
analyz
molecular
function
npinteract
protein
candid
accord
panther
protein
profil
classif
fig
reveal
diversifi
biochem
function
enrich
nucleic
acidbind
protein
chaperon
initi
assess
proor
antivir
role
npinteract
hostcel
protein
identifi
lcmsm
examin
effect
small
interf
rna
sirna
mediat
knockdown
kd
correspond
gene
multipl
rlcmv
express
report
gene
zsgreen
zsg
cell
fig
sirna
use
genomewid
targetplu
otp
human
sirna
librari
gene
sirnasgen
otp
latest
gener
sirna
offer
signific
advantag
previou
gener
offtarget
effect
primarili
driven
antisens
strand
microrna
mir
like
seed
activ
otp
sens
strand
modifi
favor
antisens
strand
uptak
wherea
antisens
strand
seed
region
modifi
drastic
reduc
seedrel
offtarget
addit
otp
design
foundat
smartselect
algorithm
dharmacon
wide
consid
best
algorithm
ration
sirna
design
strategi
numer
hostcel
factor
show
antilcmv
effect
increas
zsg
express
kd
gene
includ
microtubuleassoci
protein
dengu
viru
chikungunya
viru
chikv
begin
assess
potenti
biolog
implic
identifi
nphost
cell
protein
interact
select
phb
given
avail
reagent
exist
knowledg
role
cell
physiolog
evid
particip
multipl
virus
confirm
cell
transfect
sirna
specif
phb
exhibit
predict
reduc
level
phb
protein
express
fig
likewis
examin
whether
sirnamedi
reduc
express
level
zsgreen
correl
reduc
lcmv
progeni
titer
transfect
cell
sirna
target
express
streptag
protein
cell
seed
x
cellswel
plate
cultur
overnight
infect
moi
indic
rlcmv
h
pi
total
cell
lysat
prepar
protein
express
analyz
western
blot
growth
properti
rlcmv
express
streptag
protein
x
cellswel
x
cellswel
vero
x
cellswel
cell
seed
plate
cultur
overnight
infect
moi
indic
rlcmv
indic
time
pi
tcss
collect
viru
titer
determin
iffa
result
repres
mean
sd
result
three
independ
experi
e
lack
induct
ifni
cell
infect
rlcmvstrepnp
cell
infect
moi
indic
rlcmv
mockinfect
h
later
infect
sev
moi
h
pi
sev
tc
collect
use
follow
viru
inactiv
uv
treat
vero
cell
h
follow
infect
rvsv
moi
rvsv
mockinfect
rvsv
h
pi
rvsv
cell
fix
pfa
stain
crystal
violet
assess
rvsvinduc
cytopath
effect
use
control
rlcmvnp
contain
mutat
within
np
shown
abrog
np
abil
counteract
induct
ifni
product
http
nc
sirna
h
prior
infect
rlcmvzsg
found
sirnamedi
kd
dramat
inhibit
zsgreen
express
fig
associ
signific
reduct
infecti
lcmv
progeni
fig
attempt
see
interact
np
np
phb
coimmunoprecipit
unsuccess
sever
possibl
could
account
includ
interact
low
affin
high
onoff
rate
anoth
consider
minor
fraction
np
might
engag
interact
given
host
cell
protein
therefor
detect
interact
would
requir
highli
sensit
method
lcmsm
overcom
problem
use
confoc
microscopi
examin
coloc
np
phb
lcmvinfect
cell
weight
coloc
coeffici
cc
determin
take
consider
bright
channel
signal
significantli
higher
nonweight
cc
indic
presenc
brighter
pixel
coloc
region
compar
noncoloc
region
fig
cardiac
glycosid
ouabain
inhibitor
use
treat
congest
heart
failur
european
countri
phb
inhibitor
rocaglamid
flavaglin
aglaia
tree
use
tradit
chines
medicin
potent
anticanc
activ
examin
whether
pharmacolog
inhibit
phb
inhibit
lcmv
multipl
pretreat
human
hek
nonhuman
primat
vero
rodent
murin
hamster
cell
ouabain
rocaglamid
infect
rlcmvegfp
fig
ouabain
treatment
result
strong
dosedepend
inhibit
egfp
express
infect
humanand
nonhuman
primat
cell
affect
egfp
express
intens
infect
rodent
cell
fig
find
consist
rodent
express
allel
resist
ouabain
inhibit
likewis
observ
dosedepend
rocaglamid
inhibit
egfp
express
cell
line
infect
rlcmvegfp
fig
consist
find
product
infecti
lcmv
progeni
reduc
treatment
either
ouabain
rocaglamid
fig
within
concentr
rang
minim
impact
cell
viabil
fig
examin
correl
efficaci
cytotox
compound
determin
therapeut
index
ti
cc
ic
fig
wherea
rocaglamid
ti
cc
nm
ic
nm
cc
nm
ic
nm
vero
cell
respect
fig
moreov
antagonist
inhibitor
bufalin
also
exhibit
robust
antilcmv
activ
ti
cc
heat
shock
protein
hsp
endoplasmin
larg
neutral
amino
acid
transport
small
subunit
keratin
type
ii
cuticular
put
helicas
microtubuleassoci
protein
spectrin
beta
chain
rocaglamid
nm
fig
support
specif
antilcmv
activ
ouabain
rocaglamid
due
reduc
cell
viabil
gain
insight
mechan
ouabain
rocaglamid
exert
antilcmv
activ
examin
effect
compound
distinct
step
lcmv
life
cycl
first
ask
whether
ouabain
rocaglamid
affect
cell
entri
lcmv
conduct
timeofaddit
experi
treat
cell
ouabain
rocaglamid
prior
viru
inocul
h
time
inocul
h
h
pi
h
fig
sampl
use
ammonium
chlorid
start
h
pi
block
multipl
round
viru
infect
time
compound
addit
significantli
chang
number
egfpposit
cell
indic
neither
ouabain
rocaglamid
inhibit
cell
entri
lcmv
number
egfp
cell
ouabaintr
cell
reduc
timeofaddit
point
compar
vehicl
dimethyl
sulfoxid
dmso
treat
cell
similar
observ
ammonium
chloridetr
cell
thu
ouabain
inhibit
lcmv
rna
replic
gene
express
rather
late
step
lcmv
life
cycl
contrast
rocaglamid
treatment
result
neglig
number
egfp
cell
indic
rocaglamid
inhibit
viru
rna
replic
gene
transcript
investig
effect
ouabain
rocaglamid
viru
rna
synthesi
infect
cell
recombin
singlecycl
infecti
lcmv
express
egfp
treat
cell
either
ouabain
rocaglamid
seventytwo
hour
later
determin
percent
normal
egfp
express
infect
cell
fig
consist
result
timeofaddit
experi
ouabain
affect
report
egfp
express
howev
rocaglamid
reduc
egfp
express
confirm
inhibitori
effect
rocaglamid
viru
rna
synthesi
also
examin
effect
ouabain
rocaglamid
late
step
arenaviru
life
cycl
zmediat
bud
experi
transfect
cell
zstrepand
zflag
dykddddk
epitop
express
plasmid
lcmv
lasv
respect
h
posttransfect
remov
tissu
cultur
supernat
tc
wash
extens
transfect
cell
elimin
alreadi
bud
z
cultur
transfect
cell
presenc
absenc
ouabain
rocaglamid
h
determin
wb
level
z
protein
whole
cell
lysat
associ
viruslik
particl
vlp
collect
tc
treatment
rocaglamid
ouabain
caus
reduct
lcmv
lasv
z
bud
effici
fig
reproduc
find
confirm
base
result
four
independ
experi
fig
also
examin
whether
ouabain
could
interfer
step
assembl
infecti
progeni
captur
z
bud
assay
two
addit
experi
first
experi
involv
use
newli
gener
singlecycl
infecti
recombin
lcmv
express
report
gene
zsgreen
infect
moi
cell
st
infect
cell
subsequ
transfect
plasmid
express
lcmv
gpc
h
use
tc
infect
fresh
cell
monolay
nd
infect
identifi
infect
cell
base
zsgreen
express
assess
effect
ouabain
de
novo
assembl
infecti
progeni
determin
normal
ratio
nd
st
infect
zsgreen
cell
fig
second
experi
involv
infect
moi
cell
wt
lcmv
h
later
wash
infect
cell
three
time
remov
extracellular
infecti
progeni
produc
first
h
infect
fresh
media
contain
ouabain
dmso
vehicl
control
ad
h
later
determin
viru
titer
tc
fig
result
experi
consist
show
ouabain
inhibit
assembl
de
novo
extracellular
infecti
viru
combin
therapi
significantli
allevi
problem
pose
rapid
emerg
drugresist
variant
commonli
observ
monotherapi
strategi
control
rna
viru
infect
sinc
ouabain
rocaglamid
inhibit
differ
step
lcmv
life
cycl
examin
whether
use
combin
result
synergist
antilcmv
effect
experi
infect
cell
rlcmvegfp
treat
ouabain
rocaglamid
use
differ
concentr
combin
h
pi
determin
percent
egfp
express
fig
combin
treatment
ouabain
rocaglamid
result
synergist
antilcmv
activ
enhanc
condit
use
higher
concentr
ouabain
lower
concentr
rocaglamid
next
ask
whether
phb
hostcel
factor
contribut
also
multipl
viral
hemorrhag
fevercaus
lasv
treat
cell
ouabain
bufalin
rocaglamid
inocul
treat
cell
recombin
lasv
express
egfp
rlasvegfp
egfp
express
examin
h
later
similar
rlcmv
infect
lasv
multipl
restrict
ouabain
bufalin
rocaglamidetr
cell
concentr
minim
impact
cell
viabil
although
ic
valu
slightli
higher
found
lcmv
infect
system
fig
fig
ouabain
ic
nm
bufalin
ic
nm
rocaglamid
ic
nm
fig
also
test
effect
compound
target
phb
multipl
junv
consist
result
obtain
lcmv
lasv
ouabain
bufalin
rocaglamid
strongli
suppress
junv
multipl
fig
find
indic
phb
function
provir
factor
rang
mammarenavirus
identifi
phb
novel
hostcel
protein
contribut
effici
multipl
mammarenavirus
approach
use
recombin
lcmv
express
np
affin
tag
facilit
defin
np
interactom
context
lcmv
infect
recent
use
npspecif
monoclon
antibodi
mab
precipit
np
associ
cellular
protein
partner
mammarenaviru
np
interactom
king
et
al
identifi
host
protein
associ
lcmv
np
found
common
protein
filter
lcmv
np
interactom
protein
lcmv
np
interactom
document
king
et
al
differ
experiment
condit
analysi
methodolog
use
gener
lcmv
np
interactom
document
king
et
al
like
h
posttransfect
cell
wash
fresh
media
elimin
zmediat
product
vlp
absenc
compound
treatment
cultur
anoth
h
fresh
media
presenc
ouabain
roca
indic
concentr
vlp
present
tc
collect
ultracentrifug
cell
lysat
prepar
z
protein
express
vlp
cell
lysat
determin
western
blot
use
antibodi
streptag
c
flagtag
bud
effici
sampl
estim
divid
signal
intens
z
protein
associ
vlp
z
detect
cell
lysat
number
bottom
panel
c
correspond
lcmv
z
bud
effici
determin
repres
experi
result
shown
panel
e
correspond
averag
sd
four
independ
experi
includ
one
shown
panel
mean
bud
effici
dmso
treatedsampl
set
data
repres
mean
sd
four
independ
experi
f
effect
ouabain
incorpor
viral
glycoprotein
virion
cell
seed
x
cellswel
plate
cultur
overnight
infect
moi
scrlcmvzsg
st
infect
h
subsequ
transfect
pcgpc
h
pi
cell
wash
fresh
medium
elimin
infecti
viru
particl
produc
absenc
compound
treatment
cultur
anoth
h
fresh
media
presenc
ouabain
nm
oua
h
pi
tc
collect
use
infect
fresh
monolay
cell
nd
infect
seed
x
cellswel
plate
day
infect
cell
lysat
prepar
h
later
cell
lysat
prepar
zsgreen
signal
intens
measur
fluoresc
plate
reader
gpincorpor
effici
estim
divid
zsgreen
signal
intens
cell
lysat
nd
cell
lysat
st
mean
gpincorpor
effici
dmso
treat
sampl
set
data
repres
mean
sd
three
independ
experi
contribut
observ
differ
data
set
despit
progress
implement
global
proteomicsbas
screen
identifi
virushost
proteinprotein
interact
overlap
dataset
viral
system
usual
limit
howev
substanti
overlap
npinteract
protein
studi
support
overal
reliabl
system
use
result
egfpstrep
interactom
determin
cell
control
filter
nonspecif
np
interact
may
result
higher
degre
stringenc
studi
king
et
al
select
npinteract
candid
combin
inform
provid
np
interactom
report
king
et
al
one
present
work
facilit
futur
studi
character
function
biolog
implic
nphost
cell
interact
protein
test
mammarenaviru
np
except
np
tcrv
block
ifni
induct
antiifn
activ
np
map
ctermin
part
link
exonucleas
domain
present
np
ctermin
part
inhibitorb
kinas
identifi
npbind
protein
use
plasmidmedi
overexpress
transfect
cell
bind
affin
correl
np
abil
inhibit
ifni
induct
well
work
king
et
al
detect
interact
discrep
may
caus
low
express
lcmvinfect
cell
prevent
detect
lcmsm
altern
interact
could
possibl
temporarili
regul
take
place
earli
time
pi
could
mostli
absent
h
pi
time
prepar
cell
lysat
proteom
studi
futur
studi
compar
np
interactom
differ
time
infect
contribut
better
understand
dynam
nphostcel
protein
interact
na
k
atpas
wellcharacter
membran
ion
transport
compos
two
function
subunit
one
regulatori
subunit
repres
one
four
subunit
recent
evid
suggest
na
k
atpas
involv
multipl
cell
signal
pathway
independ
ionpump
function
cardiac
glycosid
inhibitor
na
k
atpas
nka
socal
cardioton
steroid
cst
eg
ouabain
bufalin
shown
inhibit
multipl
differ
virus
includ
ebola
viru
coronavirus
herp
simplex
viru
chikv
human
immunodefici
viru
adenoviru
porcin
reproduct
respiratori
syndrom
viru
differ
mechan
like
contribut
antivir
activ
cst
includ
alter
cell
function
modul
signal
activ
na
k
atpas
thu
low
concentr
ouabain
induc
conform
chang
result
activ
releas
protooncogen
tyrosin
protein
kinas
src
follow
activ
yet
unknown
downstream
signal
inhibit
instanc
cell
entri
murin
hepat
viru
mhv
howev
result
indic
ouabain
interfer
lcmv
cell
entri
addit
treatment
src
inhibitor
tbutyl
pyrazolo
pyrimidin
counteract
antilcmv
activ
ouabain
fig
nevertheless
src
signal
could
plausibl
contribut
inhibitori
effect
ouabain
junv
multipl
similarli
observ
mhv
moreov
cell
entri
junv
occur
also
clathrinmedi
endocytosi
process
affect
src
signal
ouabain
clinic
use
sever
european
countri
manag
congest
heart
failur
wherea
bufalin
test
clinic
trial
cancer
treatment
cst
digoxin
fdaapprov
sinc
treat
heart
failur
atrial
fibril
henc
opportun
repurpos
cst
potenti
therapeut
treat
infect
caus
viral
hemorrhag
fevercaus
arenavirus
phb
inhibitor
rocaglamid
appear
interfer
lcmv
rna
synthesi
bud
affect
lcmv
cell
entri
contrast
phb
report
cell
entri
receptor
chikv
hand
phb
act
viru
cell
entri
receptor
hcv
rather
phb
contribut
hcv
cell
entri
bind
cellular
raf
craf
protooncogen
serinethreonineprotein
kinas
subsequ
harvey
rat
sarcoma
protooncogen
hra
activ
induc
signal
transduct
pathway
requir
epiderm
growth
factor
receptor
egfr
mediat
hcv
cell
entri
addit
sirnamedi
kd
phb
decreas
product
fluav
find
indic
phb
involv
differ
step
life
cycl
varieti
virus
therebi
attract
target
develop
broadspectrum
antivir
drug
rocagl
group
natur
compound
includ
rocaglamid
inhibit
protein
synthesi
target
atpdepend
deadbox
rna
helicas
eukaryot
initi
factor
exert
antitumor
activ
rocagl
compound
silvestrol
inhibit
ebola
viru
multipl
like
interf
role
viral
protein
translat
focus
two
host
protein
phb
studi
proteom
approach
also
identifi
sever
npinteract
hostcel
protein
whose
kd
express
via
sirna
result
increas
lcmv
multipl
protein
includ
might
antilcmv
activ
shown
bind
nonstructur
protein
human
respiratori
syncyti
viru
hrsv
hrsv
antagon
host
ifni
respons
reduc
level
tnf
receptor
associ
factor
interact
interf
hrsv
abil
reduc
level
wherea
role
interact
remain
determin
examin
role
interact
modul
np
abil
inhibit
induct
type
ifn
interest
identifi
among
npinteract
host
cell
protein
rna
helicas
moloney
leukemia
viru
report
antivir
factor
fluav
retrovirus
observ
increas
lcmv
multipl
cell
subject
sirnamedi
kd
find
would
question
antilcmv
activ
howev
consid
lcmv
alreadi
optim
multipl
cell
increas
may
occur
rather
uniqu
condit
shown
enhanc
ifni
induct
follow
sev
infect
tank
bind
kinas
independ
manner
find
support
demonstr
interact
coimmunoprecipit
studi
document
antiifn
activ
mammarenaviru
np
correl
abil
interact
whether
interact
prevent
enhanc
ifni
induct
remain
determin
sever
member
mammalian
chaperonincontain
tcomplex
cct
identifi
promin
hit
np
interactom
mammalian
cct
critic
fold
mani
protein
import
function
divers
cellular
process
may
protect
complex
protein
topolog
within
central
caviti
biosynthesi
fold
contribut
cct
member
np
assembl
nucleocapsid
structur
could
account
presenc
np
egfp
interactom
interestingli
member
cct
implic
multipl
differ
virus
includ
rabi
viru
hcv
fluav
howev
role
cct
protein
viru
multipl
remain
unknown
may
involv
function
act
molecular
chaperon
previou
studi
document
presenc
sever
compon
includ
within
viral
replicationtranscript
complex
rtc
detect
cell
infect
lcmv
tcrv
find
togeth
detect
number
ribosom
protein
np
interactom
suggest
translat
viral
mrna
may
take
place
within
rtc
howev
rocaglamid
interfer
activ
within
viral
rtc
might
contribut
antilcmv
activ
work
document
gener
rlcmvstrepnp
use
defin
npinteractom
infect
cell
present
evid
phb
contribut
effici
multipl
mammarenavirus
use
genet
pharmacolog
inhibit
gene
consist
find
bioinformat
analysi
reveal
protein
network
associ
phb
involv
host
cell
protein
function
biolog
process
implic
viru
multipl
fig
overal
experiment
approach
describ
facilit
identif
biolog
relev
npinteract
hostcel
protein
futur
studi
elucid
role
proand
antivir
hostcel
factor
identifi
studi
mammarenaviru
multipl
advanc
understand
multipl
function
np
uncov
novel
cellular
target
develop
antimammarenavir
drug
addit
identifi
provir
hostcel
factor
drug
alreadi
approv
repurpos
therapeut
combat
human
pathogen
mammarenaviru
infect
babi
hamster
kidney
american
type
cultur
collect
atcc
hous
mous
atcc
grivet
vero
atcc
human
atcc
human
hek
atcc
cell
grown
dulbecco
modifi
eagl
medium
thermo
fisher
scientif
waltham
contain
heatinactiv
fetal
bovin
serum
mm
lglutamin
mgml
streptomycin
uml
penicillin
co
wt
recombin
lcmv
armstrong
rlcmv
arm
rlcmv
strain
gener
describ
gener
rlcmvnp
sev
strain
cantel
describ
rlcmv
lack
gpc
express
egfp
gener
revers
genet
use
procedur
previous
describ
rlcmvstrepnp
gener
revers
genet
use
similar
procedur
gener
wt
rlcmv
triseg
lcmv
express
egfp
gener
novel
rlcmv
creat
plasmid
direct
intracellular
synthesi
recombin
lcmv
genom
rna
speci
code
streptag
np
egfp
respect
fig
rlcmv
express
egfp
rlcmvegfp
gener
describ
rlcmv
express
zsgreen
rlcmvzsg
instead
egfp
gener
revers
genet
use
similar
procedur
gener
rlcmvegfp
gener
rlasv
express
egfp
rlasvegfp
describ
elsewher
triseg
recombin
liveattenu
candid
strain
junv
express
egfp
gener
describ
gener
novel
singl
cycl
rlcmv
express
zsgreen
plasmid
creat
omit
gpc
open
read
frame
orf
plasmid
use
gener
rlcmvzsg
rescu
revers
genet
use
similar
procedur
gener
lcmv
titer
determin
immunofocu
form
assay
iffa
describ
briefli
serial
viru
dilut
use
infect
vero
cell
monolay
plate
h
pi
cell
fix
paraformaldehyd
pfa
phosphatebuff
salin
pb
cell
permeabil
treatment
dilut
buffer
db
triton
pbscontain
bovin
serum
albumin
bsa
cell
stain
rat
mab
np
bio
x
cell
west
lebanon
nh
conjug
alexa
fluor
protein
label
kit
life
technolog
carlsbad
ca
vsv
titer
determin
plaqu
assay
total
cell
lysat
prepar
pd
lysi
buffer
mm
nacl
mm
trishcl
ph
glycerol
mm
mgcl
cacl
zncl
clarifi
centrifug
x
g
min
clarifi
lysat
mix
ratio
load
buffer
mm
tri
ph
sd
bromophenol
blue
glycerol
boil
min
protein
sampl
fraction
sdspage
use
gradient
polyacrylamid
gel
miniprotean
tgx
gel
biorad
hercul
ca
protein
transfer
electroblot
onto
polyvinyliden
difluorid
membran
immobilin
transfer
membran
millipor
billerica
detect
streptag
protein
membran
react
mous
monoclon
antibodi
strep
qiagen
germantown
md
egfp
takara
bio
usa
mountain
view
ca
gp
tehrmofish
scientif
rockford
il
phb
abcam
cambridg
rabbit
polyclon
antibodi
cell
signal
technolog
danver
dehydrogenas
gapdh
millipor
respect
follow
incub
appropri
horseradish
peroxidaseconjug
antimous
antirabbit
immunoglobulin
g
igg
antibodi
jackson
immunoresearch
laboratori
west
grove
pa
supersign
west
pico
femto
chemiluminesc
substrat
thermo
fisher
scientif
use
elicit
chemiluminesc
signal
visual
use
imagequ
la
imag
ge
healthcar
bioscienc
pittsburgh
pa
pull
streptag
protein
infect
cell
lysat
cell
prepar
six
dish
approxim
x
cell
total
infect
either
rlcmvstrepnp
moi
h
pi
cell
wash
three
time
icecold
pb
scrape
fresh
icecold
pb
centrifug
x
g
min
supernat
remov
cell
lyse
ml
pd
lysi
buffer
supplement
halt
proteas
phosphatas
inhibitor
cocktail
thermo
fisher
scientif
deoxyribonucleas
worthington
biochem
corpor
lakewood
nj
lysat
clarifi
centrifug
x
g
min
remov
cell
debri
clarifi
cell
lysat
incub
streptactin
sepharos
resin
qiagen
h
incub
resin
wash
three
time
pd
lysi
buffer
pd
lysi
buffer
without
pd
lysi
buffer
centrifug
x
g
min
last
wash
buffer
remov
protein
complex
associ
resin
elut
ml
pd
lysi
buffer
contain
mm
desthiobiotin
eluat
subject
tca
precipit
follow
trypsin
digest
multidimension
protein
identif
technolog
microcolumn
mudpit
microcolumn
prepar
first
creat
kasil
frit
one
end
undeactiv
outsid
diamet
od
capillari
tube
interior
diamet
agil
technolog
inc
santa
clara
ca
kasil
frit
prepar
briefli
dip
capillari
tube
kasil
potassium
silic
wellmix
solut
pq
corpor
malvern
pa
formamid
cure
h
cut
frit
length
mm
strong
cation
exchang
particl
scx
luna
diamet
pore
phenomenex
torranc
ca
pack
inhous
particl
slurri
methanol
cm
revers
phase
particl
cm
aqua
diamet
pore
phenomenex
success
pack
onto
capillari
tube
use
method
scx
load
mudpit
analysi
analyt
reversedphas
liquid
chromatographi
column
gener
pull
interior
diamet
id
od
capillari
tube
polymicro
technolog
phoenix
az
id
tip
reversedphas
particl
luna
diamet
pore
phenomenex
pack
directli
pull
column
mpa
cm
long
column
pack
wash
equilibr
mpa
buffer
b
acetonitril
formic
acid
follow
buffer
acetonitril
formic
acid
mudpit
analyt
column
assembl
use
zerodead
volum
union
upchurch
scientif
oak
harbor
wa
lcmsm
analysi
perform
agil
highpressur
lc
pump
agil
linear
quadrupol
ion
dual
cell
trap
orbitrap
velo
thermo
use
inhous
built
electrospray
stage
electrospray
perform
directli
analyt
column
appli
electrospray
ioniz
esi
voltag
tee
id
upchurch
scientif
directli
downstream
split
flow
reduc
flow
rate
nlmin
column
mudpit
experi
perform
step
correspond
buffer
c
mm
ammonium
acet
formic
acid
acetonitril
run
min
begin
gradient
data
analysi
protein
peptid
identif
perform
integr
proteom
integr
proteom
applic
san
diego
ca
http
www
integratedproteomicscom
use
prolucid
algorithm
dtaselect
paramet
werep
extrapidbdmin
spectrum
raw
file
extract
file
raw
file
use
open
sourc
rawextract
scripp
research
institut
la
jolla
ca
http
fieldsscrippsedudownloadsphp
tandem
mass
spectra
search
human
protein
databas
uniprotkb
accur
estim
peptid
probabl
fals
discoveri
rate
use
decoy
databas
contain
revers
sequenc
protein
append
target
databas
tandem
mass
spectra
match
sequenc
use
prolucid
algorithm
peptid
mass
toler
prolucid
search
done
intel
xeon
cluster
processor
run
linux
oper
system
search
space
includ
half
fulli
tryptic
peptid
candid
fell
within
mass
toler
window
miscleavag
constraint
carbamidomethyl
da
cystein
consid
static
modif
sirna
screen
cell
cellswel
plate
revers
transfect
pmol
sirna
pool
tabl
target
gene
use
lipofectamin
rnaimax
thermo
fisher
scientif
final
sirna
concentr
nm
follow
incub
co
h
posttransfect
cell
infect
moi
rlcmvzsg
sirna
target
hostcel
protein
select
base
avail
valid
sirna
sequenc
sirna
use
examin
effect
lcmv
multipl
knockdown
express
npinteract
host
cell
protein
candid
hit
correspond
genomewid
targetplu
otp
human
sirna
librari
gene
sirnasgen
dharmacon
lafayett
co
cell
x
cellswel
revers
transfect
plate
pmol
sirna
pool
target
gene
use
lipofectamin
rnaimax
final
sirna
concentr
nm
h
posttransfect
total
cell
lysat
prepar
modifi
lysi
buffer
mm
trishcl
ph
mm
nacl
triton
sodium
deoxychol
clarifi
centrifug
x
g
min
total
protein
concentr
clarifi
cell
lysat
measur
pierc
bca
protein
assay
kit
thermo
fisher
scientif
amount
protein
sampl
subject
sdspage
protein
express
sirnatarget
gene
analyz
western
blot
cell
infect
egfpor
zsgreenexpress
rlcmv
fix
pfa
pb
cell
permeabil
treatment
db
cell
stain
dapi
green
fluoresc
egfp
zsgreen
dapi
signal
measur
fluoresc
plate
reader
synergi
hybrid
multimod
micropl
reader
biotek
winooski
vt
mockand
virusinfect
cell
fix
pfa
cell
permeabil
block
treatment
db
contain
normal
goat
serum
cell
incub
primari
mous
anti
phb
antibodi
follow
secondari
antimous
igg
antibodi
conjug
alexa
fluor
antimous
subsequ
cell
stain
sampl
primari
antibodi
phb
omit
determin
background
fluoresc
visual
nuclei
dapi
fluoromountg
southernbiotech
birmingham
al
use
mount
coverslip
slide
glass
stain
cell
observ
confoc
microscop
lsm
zeiss
data
analyz
zen
softwar
zeiss
coloc
analysi
perform
pixel
pixel
basi
use
zen
softwar
zeiss
eight
green
npposit
cell
mark
everi
pixel
mark
area
plot
scatter
diagram
base
intens
level
channel
threshold
green
red
channel
determin
use
mockinfect
cell
stain
antinp
antimous
igg
antibodi
conjug
alexa
fluor
without
use
phb
antibodi
pixel
assign
valu
coloc
coeffici
cc
nonweight
cc
determin
divid
sum
greenand
redposit
pixel
sum
green
posit
pixel
calcul
repeat
eight
individu
cell
assess
specif
coloc
determin
weight
cc
take
consider
bright
channel
signal
comparison
nonweight
weight
cc
allow
us
determin
whether
brighter
pixel
present
coloc
region
compar
noncoloc
region
p
valu
determin
twotail
pair
test
use
graphpad
prism
softwar
vero
cell
seed
x
cellswel
plate
cultur
overnight
treat
serial
compound
dilut
co
h
follow
infect
rlcmvegfp
moi
compound
present
studi
endpoint
h
pi
cell
fix
pfa
pb
egfp
express
examin
fluoresc
plate
reader
synergi
hybrid
multimod
micropl
reader
biotek
mean
valu
obtain
dmsotreat
rlcmvegfpinfect
cell
set
ic
concentr
determin
use
graphpad
prism
vero
cell
seed
plate
x
cellswel
cultur
overnight
treat
serial
compound
dilut
cultur
co
h
celltit
aq
ueou
one
solut
reagent
promega
madison
wi
ad
thereaft
assay
perform
accord
manufactur
recommend
absorb
nm
obtain
use
enzymelink
immunosorb
assay
elisa
reader
spectra
max
plu
molecular
devic
sunnyval
ca
mean
valu
obtain
dmsotreat
cell
set
cc
concentr
determin
use
graphpad
prism
plasmid
express
cterminu
streptag
z
protein
pclcmvzstrep
gener
use
similar
procedur
gener
plasmid
express
cterminu
flagtag
lasv
z
protein
pclasvzflag
bud
assay
perform
previous
describ
cell
hek
plate
transfect
empti
pcagg
vector
pclcmvzstrep
pclasvzflag
use
lipofectamin
h
posttransfect
media
replac
fresh
media
incub
co
h
cell
three
time
wash
fresh
medium
remov
last
wash
medium
cell
cultur
fresh
medium
contain
ouabain
nm
rocaglamid
nm
equival
concentr
dmso
h
later
virionlik
particl
vlp
contain
tc
cell
collect
total
cell
lysat
prepar
lyse
cell
lysi
buffer
mm
trishcl
ph
mm
nacl
sodium
deoxychol
clarif
tc
cell
debri
centrifug
x
g
min
vlp
collect
ultracentrifug
x
g
min
sucros
cushion
vlp
resuspend
pb
z
express
total
cell
lysat
tc
contain
vlp
analyz
western
blot
cell
infect
rlcmvegfp
harvest
use
accutas
cell
detach
solut
innov
cell
technolog
san
diego
ca
fix
pfa
pb
egfp
express
examin
flow
cytometri
use
bd
lsr
ii
becton
dickson
data
analyz
flowjo
tree
star
inc
ashland
cell
seed
x
cellswel
plate
cultur
overnight
infect
h
subsequ
transfect
pcgpc
h
pi
cell
three
time
wash
fresh
media
elimin
infecti
viru
particl
produc
absenc
compound
treatment
cultur
anoth
h
fresh
media
presenc
nm
ouabain
vehicl
control
dmso
h
pi
tc
collect
use
infect
fresh
monolay
cell
seed
x
cellswel
plate
day
infect
cell
lysat
prepar
h
later
cell
lysat
prepar
total
cell
lysat
prepar
cell
lysi
buffer
mm
nacl
mm
trishcl
ph
mm
edta
clarifi
centrifug
x
g
min
zsgreen
signal
intens
clarifi
cell
lysat
measur
fluoresc
plate
reader
synergi
hybrid
multimod
micropl
reader
biotek
cell
seed
x
cellswel
plate
cultur
overnight
treat
combin
differ
concentr
ouabain
rocaglamid
h
infect
moi
rlcmvegfp
compound
present
cultur
medium
throughout
experi
h
pi
cell
fix
permeabil
treatment
db
stain
dapi
egfp
dapi
signal
measur
fluoresc
plate
reader
synergi
hybrid
multimod
micropl
reader
biotek
egfp
readout
normal
dapi
readout
normal
data
use
analyz
synergist
effect
two
compound
macsynergi
ii
program
data
analyz
p
valu
twotail
unpair
test
use
graphpad
prism
softwar
